drugset
drugset / Trial / NCT03541200

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

NCT03541200 ↗

Phase 2 Completed 190 enrolled Tanabe Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01

Timeline

Start
2018-04-18
Primary completion
2019-11-15
Completion
2019-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Elismetrep Small molecule — Oral

Indications

No indication recorded.